Publications by authors named "Dorst J"

Background: Waste and fraud are important problems for health insurers to deal with. With the advent of big data, these insurers are looking more and more towards data mining and machine learning methods to help in detecting waste and fraud. However, labeled data is costly and difficult to acquire as it requires expert investigators and known care providers with atypical behavior.

View Article and Find Full Text PDF

Primary lateral sclerosis (PLS) is a motor neuron disease (MND) which mainly affects upper motor neurons. Within the MND spectrum, PLS is much more slowly progressive than amyotrophic laterals sclerosis (ALS). `Classical` ALS is characterized by catabolism and abnormal energy metabolism preceding onset of motor symptoms, and previous studies indicated that the disease progression of ALS involves hypothalamic atrophy.

View Article and Find Full Text PDF

Background: Fasudil is a small molecule inhibitor of Rho-associated kinase (ROCK) and is approved for the treatment of subarachnoid haemorrhage. In preclinical studies, fasudil has been shown to attenuate neurodegeneration, modulate neuroinflammation, and foster axonal regeneration. We aimed to investigate the safety, tolerability, and efficacy of fasudil in patients with amyotrophic lateral sclerosis.

View Article and Find Full Text PDF

Background: This prospective study investigates the pattern of pareses in 5q-associated spinal muscular atrophy (SMA) to identify disease-specific characteristics and potential differences from amyotrophic lateral sclerosis (ALS) and spinobulbar muscular atrophy (SBMA). Detailed knowledge about pareses patterns in SMA facilitates differential diagnosis and supports therapeutic monitoring.

Methods: Between January 2021, and June 2021, 66 SMA patients (59.

View Article and Find Full Text PDF
Article Synopsis
  • * In a study involving 790 ALS patients and 570 control participants, levels of NfL and pNfH were measured, revealing that NfL is more effective than pNfH for diagnostics and prognosis, especially when considering a new population-based ALS Z-score.
  • * The research highlights the importance of factors like age, ALS symptoms, body mass index (BMI), and kidney function in interpreting neurofilament levels, showing that with
View Article and Find Full Text PDF

Background And Objectives: Autoimmune nodopathies with antibodies against the paranodal proteins show a distinct phenotype of a severe sensorimotor neuropathy. In some patients, complete remission can be achieved after treatment with rituximab whereas others show a chronic course. For optimal planning of treatment, predicting the course of disease and therapeutic response is crucial.

View Article and Find Full Text PDF
Article Synopsis
  • Pathogenic variants in the SOD1 gene are found in about 2% of sporadic and 11% of familial ALS cases in Europe, with a focus on three main variants (R116G, D91A, L145F) in a study of 83 patients in Germany.
  • Patients with the R116G variant experienced the most severe disease progression, with a median survival of just 22 months, significantly shorter than those with D91A (198 months) and L145F (87 months).
  • All patients treated with tofersen showed reduced neurofilament light chain levels in their serum, indicating a potential treatment benefit, regardless of their specific SOD1 variant.
View Article and Find Full Text PDF
Article Synopsis
  • This multicenter study evaluated tofersen treatment for patients with SOD1-ALS, focusing on clinical outcomes and patient-reported outcomes (PRO) after at least 6 months of treatment.
  • Results showed a 25% reduction in ALS progression rate, stable lung capacity, and a significant decrease in serum neurofilament light chain levels, indicating a positive response to the drug.
  • Patients reported high satisfaction with tofersen treatment, showing improved symptom severity and a strong willingness to recommend the drug to others.
View Article and Find Full Text PDF

Introduction: Amyotrophic lateral sclerosis (ALS) is an inevitably fatal condition that leads to a progressive loss of physical functioning, which results in a high psychosocial burden and organizational challenges related to medical care. Multidimensional and multiprofessional care is advised to meet the complex needs of patients and their families. Many healthcare systems, including Germany, may not be able to meet these needs because non-medical services such as psychological support or social counselling are not regularly included in the care of patients with ALS (pwALS).

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the relationship between serum neurofilament light chain (sNfL) levels and different clinical forms of amyotrophic lateral sclerosis (ALS) in nearly 3000 patients across Germany and Austria.
  • Results indicated that sNfL levels varied significantly across ALS phenotypes, with higher levels associated with faster disease progression and bulbar onset, while primary lateral sclerosis (PLS) and some other phenotypes showed lower levels.
  • The findings suggest that understanding these phenotypes is crucial for interpreting sNfL results and could influence clinical trials and practice in ALS management.
View Article and Find Full Text PDF

The integrity of the blood-CSF barrier plays a major role in inflammation, but also in shielding the CNS from external and systemic-potentially toxic-factors. Here we report results of measurements of the albumin quotient-which is thought to mirror the integrity of the blood-CSF barrier-in 1059 patients with amyotrophic lateral sclerosis. The results were compared with groups of patients suffering from Alzheimer's disease, facial palsy and tension headache.

View Article and Find Full Text PDF

Background And Purpose: The predictive value of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) for apheresis outcome in steroid-refractory multiple sclerosis (MS) relapse has not yet been evaluated.

Methods: We used pre- and postapheresis serum samples from 38 participants of the IAPEMS trial (clinicaltrials.gov: NCT02671682), which investigated the use of immunoadsorption versus plasma exchange for the treatment of steroid-refractory MS attacks.

View Article and Find Full Text PDF

Background/objective: Insufficiency of respiratory muscles is the most important reason for mortality in the natural history of SMA. Thus, improvement or stabilization of respiratory function by disease-modifying therapies (DMT) is a very important issue.

Methods: We examined respiratory function using forced vital capacity (FVC) in 42 adult SMA patients (2 SMA type 1, 15 SMA type 2, 24 SMA type 3, 1 SMA type 4, median age 37 years, range 17-61 years) treated with nusinersen for a median of 22.

View Article and Find Full Text PDF

Hydrocarbon contaminated soils resulting from human activities pose a risk to the natural environment, including in the Arctic and Antarctic. Engineered biopiles constructed at Casey Station, Antarctica, have proven to be an effective strategy for remediating hydrocarbon contaminated soils, with active ex-situ remediation resulting in significant reductions in hydrocarbons, even in the extreme Antarctic climate. However, the use of urea-based fertilisers, whilst providing a nitrogen source for bioremediation, has also altered the natural soil chemistry leading to increases in pH, ammonium and nitrite.

View Article and Find Full Text PDF

Background: Validation of the 2020 consensus criteria for primary lateral sclerosis (PLS) is essential for their use in clinical practice and future trials.

Methods: In a large cohort of patients diagnosed with PLS by expert opinion prior to the new criteria with detailed clinical baseline evaluation (n=107) and longitudinal follow-up (n=63), we applied the new diagnostic criteria and analysed the clinical phenotype, electromyography (EMG), diagnostic accuracy and prognosis, adding neurofilaments and MRI as potential biomarkers.

Results: The criteria for definite PLS were met by 28% and those for probable PLS by 19%, whereas 53% did not meet the full criteria at baseline, mainly due to the time, EMG and region criteria.

View Article and Find Full Text PDF
Article Synopsis
  • - In April 2023, tofersen, an antisense oligonucleotide, was FDA-approved for treating ALS after it significantly reduced levels of neurofilament light chain (NfL), a marker of neurodegeneration.
  • - A follow-up study involving 24 ALS patients in Germany showed that while ALS functional scores declined, there was a notable reduction in both serum NfL and phosphorylated neurofilament heavy chain (pNfH) levels in the cerebrospinal fluid (CSF).
  • - The therapy was considered safe, with no ongoing symptoms, despite some patients showing signs of immune response in the CSF, pointing to potential autoimmune reactions.
View Article and Find Full Text PDF
Article Synopsis
  • A 2016 study tested the effectiveness of 1 mg rasagiline per day as an additional treatment for 252 ALS patients, aiming to identify which subgroups may benefit most from the drug.
  • New analyses revealed that ALS patients with very slow disease progression showed better survival rates without treatment, while those with intermediate to fast progression benefited from rasagiline, showing increased survival at 6 and 12 months.
  • The study found no clear link between genetic variations in the MAOB and DRD2 genes and rasagiline's treatment effects, emphasizing the importance of factoring in individual disease progression in future ALS research.
View Article and Find Full Text PDF

Background And Purpose: Rasagiline might be disease modifying in patients with amyotrophic lateral sclerosis (ALS). The aim was to evaluate the effect of rasagiline 2 mg/day on neurofilament light chain (NfL), a prognostic biomarker in ALS.

Methods: In 65 patients with ALS randomized in a 3:1 ratio to rasagiline 2 mg/day (n = 48) or placebo (n = 17) in a completed randomized controlled multicentre trial, NfL levels in plasma were measured at baseline, month 6 and month 12.

View Article and Find Full Text PDF

Background: ALS patients with hexanucleotide expansion in C9orf72 are characterized by a specific clinical phenotype, including more aggressive disease course and cognitive decline. Computerized multiparametric MRI with gray matter volumetry and diffusion tensor imaging (DTI) to analyze white matter structural connectivity is a potential in vivo biomarker.

Objective: The objective of this study was to develop a multiparametric MRI signature in a large cohort of ALS patients with C9orf72 mutations.

View Article and Find Full Text PDF

Background And Objectives: Motor Neuron Diseases (MND) are rare diseases but have a high impact on affected individuals and society. This study aims to perform an economic evaluation of MND in Germany.

Methods: Primary patient-reported data were collected including individual impairment, the use of medical and non-medical resources, and self-rated Health-Related Quality of Life (HRQoL).

View Article and Find Full Text PDF
Article Synopsis
  • New intrathecal antisense oligonucleotide therapies are being developed for motoneuron diseases like familial amyotrophic lateral sclerosis, prompting a study of sporadic cases to identify genetic mutations.
  • Researchers screened 2,340 patients for variants in 36 ALS-associated genes, completing genetic analysis on 2,267 patients and identifying 79 likely pathogenic and 10 pathogenic variants.
  • The study found that around 13% of the cohort could be genetically resolved, suggesting the presence of both known and novel variants and shedding light on the complexities of genetic factors contributing to ALS outcomes.
View Article and Find Full Text PDF

Introduction: Amyotrophic Lateral Sclerosis (ALS) is characterized by progressive motoneuron degeneration through cell autonomous and non-cell autonomous mechanisms; and the involvement of the innate and adaptive immune system has been hypothesized based on human and murine model data. We have explored if B-cell activation and IgG responses, as detected by IgG Oligoclonal bands (OCB) in serum and cerebrospinal fluid, were associated with ALS or with a subgroup of patients with distinct clinical features.

Methods: IgG OCB were determined in patients affected by ALS (n=457), Alzheimer Disease (n=516), Mild Cognitive Impairment (n=91), Tension-type Headache (n=152) and idiopathic Facial Palsy (n=94).

View Article and Find Full Text PDF

Background: The characterisation of presymptomatic disease-burden patterns in asymptomatic mutation carriers has a dual academic and clinical relevance. The understanding of disease propagation mechanisms is of considerable conceptual interests, and defining the optimal time of pharmacological intervention is essential for improved clinical trial outcomes.

Methods: In a prospective, multimodal neuroimaging study, 22 asymptomatic C9orf72 GGGGCC hexanucleotide repeat carriers, 13 asymptomatic subjects with SOD1, and 54 "gene-negative" ALS kindreds were enrolled.

View Article and Find Full Text PDF

Aim: To describe a Delphi study regarding practice variation in needs assessment by Dutch home care nurses, to define practice variation in home care nursing and explore which factors may have a role in this needs assessment.

Design: A Delphi study was conducted with the participation of home care representatives.

Method: A Delphi questionnaire was developed, preceded by literature research and an expert meeting.

View Article and Find Full Text PDF
Article Synopsis
  • The GGGGCC hexanucleotide expansion in a non-coding region is the leading genetic cause of familial amyotrophic lateral sclerosis (ALS), based on a study involving 248 patients over nearly a decade.
  • Clinical features analyzed included age of onset, family history, and progression rates, revealing that bulbar onset was more common in patients with this genetic mutation compared to sporadic cases.
  • Patients with the GGGGCC expansion had a later age of onset and shorter median survival compared to those with other mutations and sporadic ALS, with elevated levels of phosphorylated neurofilament heavy chains in their cerebrospinal fluid (CSF).
View Article and Find Full Text PDF